Skip to main content
. 2017 Jan 16;6(1):e287. doi: 10.1038/oncsis.2016.89

Figure 4.

Figure 4

BAF180's tumor-suppressive or -promoting activity in ccRCC cell lines is HIF1α or HIF2α dependent. (a) Western blot analysis of HIF1α and BAF180 protein in parental 786-0 (parental), 786-0 with HIF1α re-expression (BAF180 WT/HIF1A cDNA) and 786-0 with HIF1α re-expression, but PBRM1 knockout by sgRNA #1, clone #1 and clone #2 (BAF180 KO-1 or -2/HIF1A cDNA). (b, c) Quantification (b) and photos (c) of clonogenic survival assay in the indicated 786-O cells. (d) Western blot analysis of BAF180, HIF1α and HIF2α proteins in SLR25/Tet-on BAF180 cells stably targeted with control, HIF1A or HIF2A shRNA in the absence of (−) or presence of doxycycline (+). (e, f) Quantification (e) and photos (f) of clonogenic survival assay of the SLR25/Tet-on BAF180 cells stably targeted with control, HIF1A or HIF2A shRNA in the absence of (−) or presence of doxycycline (+). All the samples are normalized to SCR non-targeting shRNA without doxycycline treatment.